Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium docusate + sorbitol (marketed under the brand name Klyx) is a combination rectal enema product used for the treatment of constipation, including rectal fecal impaction, and for bowel cleansing prior to medical procedures such as sigmoidoscopy. It contains two active ingredients: sodium docusate, a surfactant and stool softener that promotes water retention in stools to soften them, and sorbitol, an osmotic laxative that draws water into the bowel to stimulate evacuation. Administered rectally, the enema typically produces a bowel movement within minutes. The combination has been evaluated in clinical trials, including pediatric studies comparing its efficacy to high-dose polyethylene glycol 3350 (PEG 3350) for rectal fecal impaction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium docusate + sorbitol.